Scope of the Study
The human microbiome is the combination of all microbiota that exist in on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside including saliva, mammary glands, skin, uterus, lung, and so on. The human microbiome plays a main role in modern healthcare, as it allows easy digestion of food, regulation of the immune system, and production of vitamins such as Vitamin K, Vitamin B, and Vitamin B12, which is necessary for blood coagulation. According to the Research for Disease Control and prevention in 2015, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the U.S., moving over 500,000 people and reason about 29,000 deaths each year
The market study is being classified by Type (Probiotics, Prebiotics, Foods, Medical Foods, Diagnostic Tests, Drugs and Others), by Application (Therapeutics, Diagnostics and Others) and major geographies with country level break-up.
4D Pharma (United Kingdom), Yakult Honsha Co., Ltd (Japan), DuPont (United States), Rebiotix, Inc. (United States), Metabiomics Corporation (United States), Second Genome Inc (United States), AstraZeneca (United Kingdom), Merck & Co., Inc (United States), Synthetic Biologics, Inc. (United States), Seres Therapeutics (United States) and Microbiome Therapeutics LLC (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Vedanta BioSciences (United States), Seres Therapeutics (United States), Enterome Bioscience (France) and Seres Therapeutics (United States).
he companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Human Micobiome market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Human Micobiome market by Type, Application and Region.
On the basis of geography, the market of Human Micobiome has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Mounting prevalence of gastrointestinal disorder and cancer
- Increasing Number of Cancer Cases
- Lack of Expertise and Detailed Research
- Obstruction in Proving the Causal Link Between Disease and Dysbiosis
- The growing need for early detection and diagnostics of cancer is expected to boost demand and create the opportunities of growth for the human microbiome market.
- Stringent Government Regulations
Key Target AudienceHuman Microbiome Solution vendors, Original Equipment Manufacturers (OEMs), System integrators, Advisory firms, National regulatory authorities, Venture capitalists, Private equity groups, Investment houses and Equity research firms
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase